Management of Stage 3b CKD with Albuminuria

Introduction to CKD Management

The American Journal of Kidney Diseases recommends nephrologist involvement for eGFR <45 mL/min/1.73 m², and referral at eGFR 39 mL/min/1.73 m² is already appropriate 1, 2, 3, 4
The National Kidney Foundation guidelines suggest that patients with Stage 3b CKD and albuminuria are at high risk for progression, with an albumin-to-creatinine ratio (ACR) of 100 mg/g indicating moderately increased albuminuria 5
Late referral is associated with increased mortality after dialysis initiation, making timely referral critical 2, 3, 4

The American College of Physicians recommends referring patients to a nephrologist when eGFR is <45 mL/min/1.73 m², as guidelines suggest nephrologist involvement at this stage 1, 2, 3, 4
The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines recommend starting ACE inhibitor or ARB immediately for patients with ACR >30 mg/g to reduce proteinuria and slow CKD progression, with a Grade 1B recommendation 5, 6
Monitor for up to 30% increase in serum creatinine after initiation of ACE inhibitor or ARB, which is expected and should not prompt discontinuation unless volume depletion is present 6

The American Heart Association recommends targeting blood pressure ≤130/80 mmHg for patients with CKD and albuminuria, with a systolic BP target of 130-139 mmHg for patients >65 years, avoiding <120 mmHg 5
Hypertension is both a cause and complication of CKD and must be carefully controlled, according to the European Renal Association 2, 3, 4

The National Institute of Diabetes and Digestive and Kidney Diseases recommends monitoring eGFR, urine albumin-to-creatinine ratio (ACR), serum electrolytes, blood pressure, and weight every 3 months 5, 6, 7
Monitor complete metabolic panel, including calcium, phosphate, bicarbonate, every 3-6 months, and hemoglobin and iron studies if indicated for anemia evaluation 6
Check parathyroid hormone (PTH) if phosphorus control requires intervention, targeting intact PTH <100 pg/mL, and lipid panel every 3 months with targets of LDL <100 mg/dL 6, 7

The American College of Cardiology recommends prioritizing cardiovascular risk reduction alongside kidney-protective measures, as the vast majority of Stage 3 CKD patients die from cardiovascular causes, not progression to ESRD 1
Sodium restriction <2 g/day, smoking cessation, and exercise 30 minutes 5 times weekly are recommended for cardiovascular risk reduction 5

The European Renal Association recommends avoiding or minimizing NSAIDs, iodinated contrast, and reviewing all medications for appropriate dose adjustments based on current eGFR 5, 6, 7
Many antibiotics and oral hypoglycemic agents require dose adjustment at this eGFR level, and verifying dosing at each visit as eGFR changes is crucial 7

The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines define rapid kidney function decline as ≥30% decrease in eGFR over 2 years, and change in eGFR category plus ≥25% decline confirms true progression rather than normal fluctuation 5, 8
Rising ACR suggests progression even if eGFR is stable, according to the National Kidney Foundation 8

The American Journal of Kidney Diseases recommends not discontinuing RAAS blockade prematurely, as up to 30% increase in creatinine after starting ACE inhibitor/ARB is acceptable and expected, and only discontinuing if volume depletion is present or creatinine rises >30% 6
Referral at eGFR 39 mL/min/1.73 m² is already appropriate, and waiting until eGFR <30 risks late referral complications, according to the National Institute of Diabetes and Digestive and Kidney Diseases 1, 2, 3, 4
CKD is an independent cardiovascular risk factor, and aggressive cardiovascular risk modification is as important as kidney-protective measures, recommends the American College of Cardiology 1
If diabetic, target HbA1c ≤7.0% (or ≤8.0% if elderly with hypoglycemia risk), and consider SGLT2 inhibitor as these reduce CKD progression and cardiovascular events, according to the American Diabetes Association 5